^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    1d
    ASPENOVA: A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
    New P3 trial • Platinum resistant
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CCNE1 (Cyclin E1) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    paclitaxel • azenosertib (ZN-c3)
    1d
    A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P3, N=404, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    paclitaxel • topotecan • trastuzumab brengitecan (BL-M07D1)
    3d
    BL-B01D1-310: A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) (clinicaltrials.gov)
    P3, N=384, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    paclitaxel • topotecan • izalontamab brengitecan (BL-B01D1)
    8d
    Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Chong Kun Dang Pharmaceutical
    New P1 trial
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    8d
    ANTARES: Agnostic Therapy in Rare Solid Tumors (clinicaltrials.gov)
    P2, N=28, Recruiting, Instituto do Cancer do Estado de São Paulo | Active, not recruiting --> Recruiting
    Enrollment open • IO biomarker • Pan tumor
    |
    FH (Fumarate Hydratase) • MITF (Melanocyte Inducing Transcription Factor)
    |
    Opdivo (nivolumab)
    8d
    DENALI: A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=310, Recruiting, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | N=170 --> 310
    Enrollment change • Platinum resistant
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CCNE1 (Cyclin E1) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    azenosertib (ZN-c3)
    10d
    PRESERVE-004: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, OncoC4, Inc. | Trial primary completion date: Oct 2025 --> Aug 2026
    Trial primary completion date • Platinum resistant
    |
    Keytruda (pembrolizumab) • gotistobart (BNT316)
    10d
    MRD: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Imunon | Trial completion date: Jan 2028 --> Aug 2028 | Trial primary completion date: Aug 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • IMNN-001
    10d
    Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study (clinicaltrials.gov)
    P=N/A, N=200, Completed, Cancer Trials Ireland | Active, not recruiting --> Completed | Trial completion date: Nov 2025 --> Mar 2026
    Trial completion • Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    10d
    An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib (clinicaltrials.gov)
    P2, N=53, Recruiting, University of Colorado, Denver | Trial completion date: Oct 2028 --> Jan 2031 | Trial primary completion date: Jan 2028 --> Jan 2029
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Elahere (mirvetuximab soravtansine-gynx)
    14d
    PRESERVE-009: Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, OncoC4, Inc. | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date
    |
    gotistobart (BNT316) • AI-061